Press Releases Biodexa Pharmaceuticals Plc

Equities

BDRX

US59564R7089

Real-time Estimate Cboe BZX Other stock markets 01:20:04 2024-05-23 pm EDT			5-day change	1st Jan Change
1.16 ^USD	-9.38%		-7.26%	-57.09%

May. 22	European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	MT
May. 21	Sector Update: Health Care Stocks Advance Late Afternoon	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises	May. 22	AQ
Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting	May. 21	AQ
Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting	Apr. 30	AQ
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)	Apr. 26	AQ
Preliminary Results for the Year Ended 31 December 2023	Apr. 19	AQ
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update	Feb. 23	AQ
Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients	Feb. 08	AQ
Biodexa Announces Allowance of U.S. Patent Covering Tolimidone	Feb. 07	AQ
Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024	Jan. 22	AQ
Biodexa Appoints Ann Merchant to the Board of Directors	Dec. 29	AQ
Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option	Dec. 21	AQ
Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering	Dec. 19	AQ
Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes	Nov. 27	AQ
Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma	23-10-03	AQ
Biodexa Pharmaceuticals : SUBMITTED HEREWITH - Form 6-K	23-09-29	PU
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)	23-09-21	AQ
Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites	23-07-28	AQ
Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement	23-07-24	AQ
Midatech Pharma : Biodexa Pharmaceuticals PLC?Annual Report 2022Biodexa Pharmaceuticals PLC(formerly Midatech Pharma Plc)Annual Report 2022 - Form 6-K	23-06-01	PU
Midatech Pharma : Notice of 2023 AGM	23-05-21	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Biodexa Pharmaceuticals Plc

Equities

BDRX

US59564R7089

Press Releases

Filters